Clinical Trial Update: Lirilumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating lirilumab with azacitidine in refractory or relapsed acute myeloid leukemia was terminated; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
• Biphenotypic Leukemia

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• lirilumab (lirilumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Acute Biphenotypic Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Phase 2 | Status: TERMINATED | Results posted: 2019-09-24